The MarketVue®: Netherton’s Syndrome market landscape report combines primary (KOL interviews) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.
Topics covered in this report:
- Disease overview: Review the disease pathophysiology and potential druggable targets
- Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
- Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
- Unmet needs: Identify opportunities to address treatment or disease management gaps
- Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
- Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing
Methodology:
Research for the MarketVue®: Netherton’s Syndrome report is supported by 8 qualitative interviews with key opinion leaders and secondary research.
Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom).
Key companies mentioned:
- Quoin Pharmaceuticals
- Lifemax Laboratories
- Sixera Pharma
- Daiichi Sankyo
Key drugs mentioned:
- Triamcinolone
- Calcineurin
- Ustekinumab (Stelara)
- Secukinumab (Cosentyx)
- QRX003
- Dupilumab (Dupixent)
- LM-030
- SXR1096
- DS-2325a
Table of Contents
1. DISEASE OVERVIEW
- A rare, inherited disorder of the skin characterized by scaling skin, bamboo hair, and increased susceptibility to infection
- Figure 1.1. Clinical presentation of NS and related targets
- NS falls under the category of autosomal recessive congenital ichthyoses
- Figure 1.2. Classification of NS
- Table 1.1. Severity of NS is typically dependent on body involvement though severity assessments exist
2. EPIDEMIOLOGY & PATIENT POPULATIONS
- Disease definition
- Figure 2.1. G6 diagnosed prevalent cases of NS by region
- Table 2.1 Diagnosed prevalent and drug-treated patients in the G6
3. DIAGNOSIS AND CURRENT TREATMENT
- Diagnosis overview
- Figure 3.1. Diagnostic work-up for NS patients
- Physician insights on diagnosis of NS
- Treatment of NS
- Treatment overview
- Figure 3.2. Treatment goals for NS
- Treatment flow for NS
- Figure 3.3. Treatment algorithm for NS
- Upsides and downsides of current NS treatment options
- Physician perspectives on off-label biologics
- Figure 3.4. Reservations around off-label biologic use in NS
- Key treatment dynamics that shape disease management in NS
- Figure 3.5 . Must-know NS treatment dynamics for now and the future
4. UNMET NEED
- Overview
- Figure 4.1. Physician-reported top unmet needs in NS patients
- Other unmet needs for NS
5. PIPELINE ANALYSIS
- Overview
- Table 5.1. Emerging NS therapies, phase 1 to phase 3
- The promising future of disease-modifying biologics
- Figure 5.1. Advantages of a disease-modifying biologic in NS
6. VALUE & ACCESS
- Overview
- Figure 6.1. Reimbursement and access considerations for emerging therapies in NS
- Table 6.1. Current therapy pricing, U.S. 2021-2022
- Biologics face a rigorous approval process on commercial insurance plans
- Dupixent for the use of atopic dermatitis and eosinophilic esophagitis as an analogue for potential NS therapies
- Figure 6.2. Commercial insurance restrictions on Dupixent’s use in AD and EoE
7. METHODOLOGY
- Primary market research approach
- Epidemiology methodology
Samples
LOADING...
Companies Mentioned
- Quoin Pharmaceuticals
- Lifemax Laboratories
- Sixera Pharma
- Daiichi Sankyo
